About CLS Investment Criteria Our Team Scientific Advisors Portfolio News Contact
 
 
     
 

APT Pharmaceuticals Secures $32 Million in Series B Financing
September 30, 2008


XLumena Spots $6M For Ultrasound Devices
June 4, 2008


Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
APRIL 28, 2008


Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors
APRIL 25, 2008


EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients
February 26, 2008


KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing
February 20, 2008


EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
January 8, 2008


EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity
January 7, 2008


CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy
January 7, 2008


APT Pharmaceuticals Expands Management Team
NOVEMBER 19, 2007


EnteroMedics Announces Initial Public Offering
NOVEMBER 14, 2007


APT Pharmaceuticals Closes New $22 Million Funding Round
OCTOBER 4, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
SEPTEMBER 20, 2007


Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids
AUGUST 21, 2007


KFx Medical Corporation Closes $10 Million Series B Financing
AUGUST 9, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
JUNE 18, 2007


CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President
JUNE 6, 2007


APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection
JUNE 5, 2007


Enteromedics Files Registration Statement
for Proposed Initial Public Offering
MAY 25, 2007


CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
APRIL 10, 2007


Athenagen Announces Name Change to CoMentis
FEBRUARY 10, 2007


Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study
JANUARY 31, 2007


Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease
DECEMBER 13, 2006


Mirabilis Medica Names Mike Connolly CEO
OCTOBER 3, 2006


Athenagen Raises $50 Million in Series B Financing
SEPTEMBER 28, 2006


Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents
SEPTEMBER 26, 2006


Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids
AUGUST 29, 2006


Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD
AUGUST 21, 2006


Athenagen Completes Merger with Zapaq
AUGUST 14, 2006


KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation
AUGUST 10, 2006


Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia
JUNE 15, 2006


Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline
APRIL 13, 2006


Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
MARCH 23, 2006


Athenagen Adds A. Barr Dolan to its Board of Directors
FEBRUARY 22, 2006


Previous News Stories >

 
     
 

KFx Medical Corporation Appoints Matt Meyer
as its Vice President Marketing

SAN DIEGO, CA – FEBRUARY 20, 2008

KFx Medical Corporation announced today the appointment of Matt Meyer as Vice President, Marketing of the orthopedic tissue repair company.

Previously, Mr. Meyer was Group Director at Medtronic (NYSE: MDT) with its Spinal and Biologics business in Memphis, Tenn. During his 10 year career with Medtronic Sofamor Danek, Mr. Meyer had marketing responsibility for businesses in excess of $700 million. He rapidly rose through the ranks of account representative and product management with substantial and continual year over year growth in his assigned products. Prior to Medtronic, he worked at DePuy Motech, now a Johnson and Johnson company (NYSE:JNJ), as a sales representative. After earning his undergraduate degree at Virginia Tech he served in US Army with Infantry and Special Forces units.

"Matt is a great addition to our management team. His considerable success with orthopedic multinationals in branding, project management, and meeting aggressive growth objectives will help us greatly as we further our market expansion in rotator cuff repair and enter multiple new markets later this year," remarked Tate Scott, KFx’s president and CEO.

"I am excited to join KFx at this critical time for the company. KFx is committed to developing innovative implant systems that insure patients receive secure, anatomic, soft tissue re-attachment in a host of orthopaedic applications," said Mr. Meyer.

KFx Medical recently completed a Series B Financing of $10 million lead by Alloy Ventures.

Over four million people seek medical advice for shoulder pain every year; torn rotator cuffs alone account for more than 500,000 surgeries annually and have traditionally required many weeks of rehabilitation. Traditional minimally invasive techniques, although promising — (patients typically experience less pain and regain full range of motion more quickly) — require surgeons to have advanced arthroscopic skills. In contrast, KFx provides simple systems for surgeons while ensuring more anatomical repair for the patient, yielding better clinical outcomes.

About KFx Medical Corporation
Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop clinically relevant solutions to rotator cuff repair. The company is privately held – Investors include Alloy Ventures, Charter Life Sciences, Arboretum Ventures, Montreux Equity Partners, and MB Ventures.

 

For more information: www.KFxmed.com

 

CONTACT:
Tate Scott
KFx Medical Corporation
5845 Avenida Encinas, Ste 128
Carlsbad, CA 92008
760 444-8820
TateScott@kfxmed.com

 
     
     
     
     
   
 
 
© 2006 CHARTER LIFE SCIENCES